SUMMARY Plasma enteroglucagon was measured before and during three hours after a standard meal in 21 untreated adult patients with suspected coeliac disease who all had villous atrophy of the small intestinal mucosa and malabsorption, and in nine control subjects. In 11 of these patients the diagnosis of coeliac disease was confirmed and 10 were again investigated on a gluten free diet. The coeliac patients had higher basal (37±9 pmol/l, mean ± SE, p<0-05) and postprandial (70±9 pmol/l, p<0-005) mean plasma enteroglucagon concentrations than the control subjects (basal 14±4 pmol/l, postprandial 25±5 pmol/l). The 10 coeliac patients on gluten free diet for five to 20 months had a basal mean plasma enteroglucagon concentration not significantly lower than before treatment (25±5 pmol/l) but significantly lower postprandial enteroglucagon concentrations than before treatment (40±7 pmol/l, p<0.025). Postprandial plasma enteroglucagon concentration after 90 minutes in untreated patients correlated positively to the faecal fat excretion (r=0.58, p<002). It correlated negatively to the urinary five hour D-xylose excretion after an oral load of 165 nimol D-xylose (r=-0.71, p<0.01). Thus, the postprandial plasma enteroglucagon concentrations in untreated coeliac disease were related to the degree of malabsorption and they normalised during treatment with a gluten free diet.
Biological activity similar to pancreatic glucagon has long been known to occur in the intestine. The presence of glucagon like immunoreactants also became evident after the development of glucagon radioimmunoassay. Purified preparations of 'enteroglucagon' from porcine intestine have been reported to be composed of the pancreatic glucagon amino acid sequence of 29 amino acids and a C-terminal octapeptide extension.' Antibodies against the Nterminal part of the glucagon molecule may cross react completely with enteroglucagon, but those against the C-terminal part may have negligible such cross reactivity.2 Enteroglucagon is located within the mucosal L-cells with a maximal concentration in the distal small intestine.3 It is released into the circulation after an oral glucose load or a mixed meal.4 Plasma enteroglucagon concentrations are increased greatly by intrajejunal glucose infusion and moderately by triglycerides whereas they are unchanged after infusion of hyperosmolal sodium chloride. 5 The physiological role of enteroglucagon in man is so far unknown but a trophic effect on the with untreated coeliac disease.8 Coeliac patients treated with a gluten free diet have, however, normal enteroglucagon concentrations. It has therefore been suggested that determination of plasma enteroglucagon might be of value for detection and follow up of patients with coeliac disease. 8 9 No studies of the same coeliac patients before and after gluten withdrawal, however, have to our knowledge been reported.
The purpose of this investigation was to determine fasting and postprandial plasma enteroglucagon concentrations in coeliac patients before and after treatment with a gluten free diet and to see if enteroglucagon assay may be useful in the follow up of the dietary treatment.
healthy volunteers were investigated. The study was approved by the ethical committee of the Medical Faculty of the University of Goteborg.
Twelve patients were studied before gluten withdrawal, nine women and three men aged between 24 and 78 years (mean age 49 years). Nine of these patients had a subtotal villous atrophy and three a partial villous atrophy of the small intestinal mucosa. The diagnosis of coeliac disease was confirmed by complete normalisation or obvious improvement of the mucosal morphology by light microscopy of a second biopsy specimen after treatment with a gluten free diet. Eleven of these patients were also studied after five to 20 months (mean 11 months) on a gluten free diet. One patient will be described separately; before the investigation for coeliac disease an intestinal resection was carried out because of a jejunal adenocarcinoma.
Nine patients, aged between 19 and 85 years (mean age 58 years), with probable coeliac disease and malabsorption, were also studied before any treatment with a gluten free diet. One patient refused any further investigations and one patient, 85 years old, died three months after the initial investigation. In two cases a second biopsy showed no improvement of the intestinal morphology; this investigation had been made three and six months, respectively, after they were prescribed a gluten free diet. 4 When measured with K 5563, the reaction with gut GLI has been found to be lower than i%.15
The difference between the dose estimates with these antibodies was taken as a measure of the plasma enteroglucagon concentration.'-3 Porcine glucagon in phosphate buffer solution (0.04 M phosphate buffer, pH 7-4, containing 1 g human albumin (Behringwerke), 6 g NaCl, and 240 kIU aprotinin/l) was used as standard and '25I-labelled pork glucagon as radioligand. Calibrators were assayed in triplicate and ethanol extracted plasma samples in duplicates. Plasma extracts were prepared by adding 18 ml 96% ethanol to 0-5 ml plasma diluted with 0-5 ml 0 04 M phosphate buffer (pH 7.4) followed by centrifugation. The supernatants were decanted to small bottles and evaporated to dryness in a desiccator. The residues were dissolved in 0-5 ml of the phosphate buffer. Calibrators and plasma samples were incubated at 4°C for 20-24 hours before addition of [1251] glucagon solution. After another 20-24 hours 96% ethanol was added to a final concentration of 85% to precipitate the antibody bound glucagon. The within assay imprecision of the glucagon assays was calculated from differences between the duplicate assays of single plasma sample extracts using values from pool samples and patient samples ( Table 1) . The within assay imprecision and bias (assay drift) for the enteroglucagon assays was calculated from A significant increase of the mean plasma enteroglucagon concentration was found in the first samples 30 minutes after initiation of the meal in both control subjects and in patients (Fig. 1 ). After The mean basal plasma enteroglucagon concentration (mean ± SE) was at all sampling times significantly higher in untreated coeliac disease (37±9 pmol/l) and in probable coeliac disease (56±12 pmol/l) than in control subjects (14+4 pmol/l). During the period 90-180 minutes the patients with coeliac disease and those with probable coeliac disease had significantly higher plasma enteroglucagon concentrations than control subjects (mean value for the four samples being 70±9 pmol/I and 100±16 pmol/l, respectively, compared with 25±5 pmol/l, p<0005).
The treated patients (n= 10) had significantly lower concentrations (40±7 pmol/l) during the period 90-180 minutes (p<0025) than before treatment, which was not significantly higher than in control subjects (Fig. 2) . The basal mean plasma enteroglucagon concentration (25 ±5 pmol/l) was not significantly lower than the pretreatment Fig. 2 Plasma enteroglucagon concentration (mean ± SE) before and after a test meal in patients with coeliac disease before (A, n=JJ) and after (A, n=J0) treatment with a gluten free diet. Time for the meal as in Fig. 1 . Symbols for degree ofstatistical significance of differences as in Fig. 1 .
concentration. The patient with jejunal resection because of adenocarcinoma had the highest postprandial plasma enteroglucagon concentration, highest value being 210 pmol/l before treatment and 70 pmol/l after treatment. An overlap of the postprandial concentrations in patients with coeliac disease and in control subjects was observed (Fig. 3) . Plasma enteroglucagon concentration either at 90, 120, or 150 minutes was found to be correlated to the faecal fat excretion (Fig. 4) . A negative correlation to the D-xylose excretion during an absorption test was found at 90, 120, 150, as well as at 180 minutes (Fig. 5) . Table 3 shows the frequency of abnormal malabsorption tests and postprandial plasma enteroglucagon concentrations above the range of the control subjects.
Discussion
This study confirms results from a previous study8
that postprandial plasma enteroglucagon concentrations are higher in untreated coeliac disease than in control subjects. It also shows that dietary treatment of these patients is followed by lower plasma enteroglucagon concentrations. Furthermore, we found that the postprandial plasma enteroglucagon concentrations were related to the group.bmj.com on October 21, 2017 -Published by http://gut.bmj.com/ Downloaded from the enteroglucagon cells is preserved and it is exposed to an increased amount of unabsorbed luminal content after a meal. Our findings of a correlation between the postprandial plasma enteroglucagon concentrations and the degree of malabsorption support the hypothesis mentioned above and indicate that the amount of unabsorbed intestinal content is important for the release of enteroglucagon.
The number of patients and control subjects in our study is too low to allow a full evaluation of the possibility that determination of plasma enteroglucagon concentrations could be used as a test for detection of coeliac. disease in adults. Postprandial values seem to separate the groups more clearly than fasting values. The fact that the postprandial plasma enteroglucagon concentrations were lower after treatment with a gluten free diet implies that it is possible to follow the improvement of the malabsorption and the adherence to the diet with repeated determinations. 
